Cytochrome P450 3A and efflux transporters (CYP3A/Efflux Transporters)

The Human CYP3A and efflux transporters (primarily P-glycoprotein/ABCB1) represent a synergistic detoxification system essential for regulating the pharmacokinetics of over 50% of marketed drugs [Wilkinson, 2005]. These proteins are co-localized in key physiological barriers, such as the intestinal epithelium and hepatocytes, where they work together to limit the systemic absorption of xenobiotics [Benet, 2009]. Efflux transporters pump substrates back into the intestinal lumen or bile, while CYP3A enzymes perform oxidative metabolism, often acting on the same substrates in a process known as the metabolism-efflux alliance [Cummins et al., 2002]. This interplay significantly influences drug bioavailability and is a primary site for clinically significant drug-drug interactions (DDIs) [FDA, 2020]. In disease states like cancer, the upregulation of efflux transporters contributes to multidrug resistance (MDR), enabling cells to evade the toxic effects of chemotherapeutic agents [Gottesman et al., 2002]. Consequently, this system is a major focus of drug development and safety assessments to ensure predictable therapeutic outcomes and minimize adverse reactions.

Other names

CYP3A and P-glycoprotein systemPhase I and Phase III detoxification systemMetabolism-efflux allianceXenobiotic metabolic and transport system

Drugs interact with this system as substrates, inhibitors, or inducers, thereby modulating the systemic exposure and clearance of co-administered medications.